Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead
PAHCâs Zoetis MFA acquisition boosts animal-health growth via vaccines and companion animals. Click for more on PAHC stock.
SeekingAlpha5 gün önceZTS
THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)
abrdn Healthcare Opportunities Fund upgraded: 10.9% yield, -4.5% NAV discount, good distribution coverage and healthcare rebound potential. Click for a THQ update.
SeekingAlpha7 gün önceZTS
TD Cowen Maintains Buy on Zoetis, Lowers Price Target to $94
TD Cowen analyst Steve Scala maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target from $104 to $94.
Benzinga10 gün önceZTS
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Yahoo14 gün önceZTS
Stifel Maintains Hold on Zoetis, Lowers Price Target to $80
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target from $85 to $80.
Benzinga15 gün önceZTS
Zoetis (ZTS) Stock Still Looks Cheap After a 62% Slide
Zoetis stock has had a tough run over the last few years, yet the current valuation checks suggest the shares may now be pricing in a lot of that bad news. After a prolonged slide, the question is whether the current market price properly reflects Zoetis' earnings power and risks. Over the past 5 years, Zoetis shareholders have seen the share price decline about 61.8%, which points to a significant reset in expectations. Recent investor focus is on how competition and softer pet care...
Yahoo15 gün önceZTS
Is Zoetis’ Lowered 2026 Outlook and Simparica Trio EUA Altering The Investment Case For Zoetis (ZTS)?
Zoetis recently received an Emergency Use Authorization from the U.S. FDA for its Simparica Trio chewable to treat life-threatening New World screwworm infestations in dogs and puppies, while also appointing experienced healthcare executive Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer. At the same time, Zoetis lowered its full-year 2026 revenue and earnings guidance, signaling a more cautious outlook even as it expands the clinical reach of one of its flagship...
Yahoo16 gün önceZTS
3 High-Yielding Dividend Stocks That Have Doubled Their Payouts in 5 Years
These stocks have been generous with their dividend increases, and more may be on the way.
Yahoo16 gün önceZTS
Zoetis: A Solid Long-Term Buy After Harsh Drawdown
Despite aggressive competitor promotions, Zoetis protects industry-leading profitability. Click here to find out why ZTS stock is a Buy.
SeekingAlpha17 gün önceZTS
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap
Zoetisâ mixed Q2 earnings and lowered guidance hit margin of safety, but long-term upside remains. Click for more on ZTS stock.
SeekingAlpha19 gün önceZTS
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense
Zoetis (ZTS) trades at 12x forward earnings with a ~3% yield after a big drawdownâsee why its margins, buybacks, and value setup make it a Buy. Read the full analysis here.
SeekingAlpha21 gün önceZTS
MOO: Farm Cycle Recovery And Long Term Food Security
Explore VanEck Agribusiness ETF (MOO): global ag exposure, discounted valuation, dividends, and catalysts vs risks.
SeekingAlpha21 gün önceZTS
Michael Burry-Backed ZTS Stock Climbs Following FDA Green Light For Dog Pill Against Screwworm
The FDA authorized Zoetis’s Simparica TRIO—already sold since 2020 for heartworm, fleas and ticks—for treating New World screwworm in dogs and puppies.
Yahoo21 gün önceZTS
Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies
PARSIPPANY, N.J., August 13, 2026--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living tissues, such as open wounds, of animals including livestock, wildlife and pets, and can inflict dam
Yahoo21 gün önceZTS
FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies
https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-treat-new-world-screwworm-dogs-and-puppies
Benzinga22 gün önceZTS
Zoetis (ZTS) Q2 2026 Earnings Call Transcript
U.S. companion animal demand weakened, but livestock and diagnostics surged.
Yahoo22 gün önceZTS
Michael Burry Adds To NBIS, MU, ORCL Shorts — Says Nebius Is ‘What The Top Of A Boom Looks Like’
'The Big Short' investor is betting against AI-linked names even as he sees strong demand for compute as a potential warning sign for the sector.
Yahoo22 gün önceZTS